Program
DA-5218
A development code. Also written as “DA-5218-C”.
Its studies are mostly in Diabetes Mellitus, led by Dong-A ST.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dong-A ST | 21 open or running | phase 4since Nov 13, 2025 | Jul 4, 2022 | Nov 2027phase 4 · NCT07229534 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 4, 2022First study: phase 1 study in HealthyFirst studyNCT05449704 · 90 enrolled · Korea, Republic of
- Nov 13, 2025Phase 4 study in Diabetes MellitusNCT07229534 · 238 planned
Ahead
- Nov 2027Primary completion: phase 4 study in Diabetes MellitusNCT07229534
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07229534Diabetes Mellitus | 4 | Not yet recruiting | Nov 2027 | 238 |
| NCT05449704Healthy · Korea, Republic of | 1 | UNKNOWN | Sep 3, 2022 | 90 |
How it is read
Names in the registry
- “DA-5218”, 2 entries
- “DA-5218-C”, 1 entry
Codes read as this program: DA5218.
Conditions, from the studies’ own filings
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.